No Data
No Data
BOC International: Continued prosperity of upstream medical beauty manufacturers opens up space for external expansion.
According to the research reports released by BOC International, the performance of leading medical and aesthetic companies is still maintaining good growth, and the average product price has not shown any price reduction pressure. The constantly enriched product matrix is expected to bring growth in the future.
Stock market fluctuations | ec healthcare (02138) fell more than 5%, with a year-on-year decline of 85.3% in net profit to 15.7 million Hong Kong dollars.
Ec healthcare (02138) fell more than 5% in intraday trading. As of press time, it fell 4.62% to HKD 1.24 with a turnover of HKD 782,700.
EC Healthcare (02138.HK) annual net profit after tax fell by 85.3% to HKD 15.7 million.
EC Healthcare (02138.HK) announced that for the fiscal year ending on March 31, 2024, the Group's revenue and sales amounted to HKD 421.10 million and HKD 421.00 million, respectively, an increase of 8.7% and 8.5% year-on-year. The Group's internal growth increased by 5.8% year-on-year to HKD 410.00 million, driven by the growth of the medical division through the introduction of additional service points since the last fiscal year and the gradual recovery of mainland tourists visiting Hong Kong, resulting in growth of aesthetic medicine, beauty, and wellness services. The Group's after-tax net profit for the reporting period remains the same.
EC Healthcare (02138) released its annual performance with a net loss of HKD 18.947 million that should be borne by shareholders, with a year-on-year profit turning into a loss.
Ec healthcare (02138) announced its annual results as of March 31, 2024. The group earned a revenue of 42...
Express News | EC Healthcare - FY Revenue HK$4.21 Bln Vs HK$3.88 Bln
Express News | EC Healthcare - FY Loss Attributable HK$18.9 Mln Vs Profit HK$69.7 Mln
No Data